XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.23.2

Stock Option | 12 Months Ended
--- | ---
Jun. 30, 2023
Stock Option |
Stock Option | NOTE 9 - Stock Options The Company follows ASC 718 (“Share-Based Payment”), which requires that all share-based payments to employees, including stock options, be recognized as compensation expense in the consolidated financial statements based on their fair values and over the requisite service period. For the fiscal years ended June 30, 2023, 2022 and 2021, the Company recorded non-cash compensation expense of $1,464,000 ($.04 per basic and diluted share), $1,649,000 ($.04 per basic and diluted share) and $435,000 ($.01 per basic and diluted share), respectively, relating to stock-based compensation. 2012 Employee Stock Option Plan In December 2012, the stockholders approved the 2012 Employee Stock Option Plan (the “2012 Employee Plan”). The 2012 Employee Plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 1,900,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options, which are intended to qualify as incentive stock options (ISOs), to valued employees. Any plan participant who is granted ISOs and possesses more than 10% of the voting rights of the Company’s outstanding common stock must be granted an option with a price of at least 110% of the fair market value on the date of grant. Under the 2012 Employee Plan, stock options may be granted to valued employees with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable, in whole or in part, at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At June 30, 2023, 521,580 stock options were outstanding, 247,628 stock options were exercisable and no further stock options were available for grant under this plan. 37,500 options were granted under this plan during the year ended June 30, 2023. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2023 |  | 2022 | ​ | 2021 |
Risk-free interest rates | ​ | 3.03 | % | 1.64 | % | n/a | ​
Expected lives | ​ | 7.27 Years | ​ | 6.18 Years | ​ | n/a | ​
Expected volatility | ​ | 43 | % | 43 | % | n/a | ​
Expected dividend yields | ​ | 0 | % | 0 | % | n/a | ​
​ The Company uses a weighted-average expected stock-price volatility assumption that is a combination of both current and historical implied volatilities of the underlying stock. The implied volatilities were obtained from publicly available data sources. For the weighted-average expected option life assumption, the Company considers the exercise behavior of past grants. The average risk-free interest rate is based on the U.S. Treasury Bond rate for the expected term of the options and the average dividend yield is based on historical experience. The following table reflects activity under the 2012 Plan for the fiscal years ended June 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2023 | ​ | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | Weighted average
​ |  | Options |  | exercise price |  | Options |  | exercise price |  | Options |  | exercise price
Outstanding, beginning of year | ​ | ​ | 523,080 | ​ | $ | 18.59 | ​ | ​ | 214,080 | ​ | $ | 9.59 | ​ | ​ | 235,680 | ​ | $ | 9.42
Granted | ​ | ​ | 37,500 | ​ | $ | 26.94 | ​ | ​ | 338,000 | ​ | $ | 23.17 | ​ | ​ | — | ​ | ​ | —
Forfeited/Lapsed | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (13,000) | ​ | ​ | 6.91
Exercised | ​ | ​ | (39,000) |  | $ | 10.44 | ​ |  | (29,000) |  | $ | 5.45 | ​ |  | (8,600) |  | ​ | 9.04
Outstanding, end of period | ​ | ​ | 521,580 | ​ | $ | 19.37 | ​ |  | 523,080 | ​ | $ | 18.59 | ​ |  | 214,080 | ​ | $ | 9.59
Exercisable, end of period | ​ | ​ | 247,628 | ​ | $ | 17.16 | ​ |  | 176,752 | ​ | $ | 14.68 | ​ |  | 98,176 | ​ | $ | 8.07
Weighted average fair value at grant date of options granted | ​ | $ | 13.36 | ​ |  | ​ | ​ | $ | 12.16 | ​ |  | ​ | ​ | $ | n/a | ​ |  | ​
Total intrinsic value of options exercised | ​ | $ | 822,000 | ​ | ​ | ​ | ​ | $ | 502,000 | ​ |  | ​ | ​ | $ | 65,000 | ​ |  | ​
Total intrinsic value of options outstanding | ​ | $ | 7,968,000 | ​ | ​ | ​ | ​ | $ | 1,916,000 | ​ |  | ​ | ​ | $ | 1,840,000 | ​ |  | ​
Total intrinsic value of options exercisable | ​ | $ | 4,330,000 | ​ | ​ | ​ | ​ | $ | 1,218,000 | ​ |  | ​ | ​ | $ | 993,000 | ​ |  | ​
​ 37,500, 338,000 and 0 options were granted during the fiscal years ended June 30, 2023, 2022 and 2021, respectively. 39,000, 29,000 and 8,600 options were exercised during the fiscal years ended June 30, 2023, 2022 and 2021, respectively. 29,600 of the 39,000 stock options exercised during the fiscal year ended June 30, 2023, were settled by exchanging 10,150 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. 1,000 of the 29,000 stock options exercised during the fiscal year ended June 30, 2022, were settled by exchanging 153 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. 8,600 stock options exercised during the fiscal year ended June 30, 2021 were settled by exchanging 4,604 shares of the Company's common stock which were retired and returned to unissued status upon receipt. $84,000, $155,000 and $0 was received from the remaining option exercises for the fiscal years ended June 30, 2023, 2022 and 2021, respectively, and the actual tax benefit realized for the tax deductions from option exercises was $0 for each of these periods. The following table summarizes information about stock options outstanding under the 2012 Employee Plan at June 30, 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ |  | ​ |  | Weighted average |  | ​ | ​ |  | ​ |  | ​ | ​
​ | ​ | Number | ​ | remaining | ​ | Weighted average | ​ | Number | ​ | Weighted average
Range of exercise prices | ​ | outstanding | ​ | contractual life | ​ | exercise price | ​ | exercisable | ​ | exercise price
$3.15 ‑ $26.94 | ​ | 521,580 | ​ | 7.67 | ​ | $ | 19.37 | ​ | 247,628 | ​ | $ | 17.16
​ | ​ | 521,580 | ​ | 7.67 | ​ | $ | 19.37 | ​ | 247,628 | ​ | $ | 17.16
​ As of June 30, 2023 and 2022, there was $1,971,000 and $2,489,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Employee Plan, respectively. 109,876, 107,576 and 44,776 options vested during the years June 30, 2023, 2022 and 2021, respectively. The total grant date fair value of the options vesting during the fiscal years ended June 30, 2022, 2021 and 2020 under this plan was $981,000, $1,040,000 and $244,000, respectively. 2012 Non-Employee Stock Option Plan In December 2012, the stockholders approved the 2012 Non-Employee Stock Option Plan (the “2012 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 100,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2012 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At June 30, 2023, 20,400 stock options were outstanding, 13,920 stock options were exercisable and 0 stock options were available for grant under this plan. No stock options were granted under this plan during the year ended June 30, 2023. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | 2023 |  | 2022 | ​ | 2021 |
Risk-free interest rates | n/a | ​ | 1.68 | % | n/a | ​
Expected lives | n/a | ​ | 6.18 Years | ​ | n/a | ​
Expected volatility | n/a | ​ | 43 | % | n/a | ​
Expected dividend yields | n/a | ​ | 0 | % | n/a | ​
​ The following table reflects activity under the 2012 Non-Employee Plan for the fiscal years ended June 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2023 | ​ | 2022 | ​ | 2021
​ |  | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average
​ | ​ | Options | ​ | exercise price | ​ | Options | ​ | exercise price | ​ | Options | ​ | exercise price
Outstanding, beginning of year | ​ | ​ | 20,400 | ​ | $ | 14.39 | ​ | ​ | 12,000 | ​ | $ | 6.55 | ​ | ​ | 24,000 | ​ | $ | 5.15
Granted | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 9,600 | ​ | $ | 22.93 | ​ | ​ | — | ​ | ​ | —
Forfeited/Lapsed | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (9,600) | ​ | $ | 3.59
Exercised | ​ | ​ | — | ​ | ​ | — | ​ |  | (1,200) |  | $ | 4.35 | ​ |  | (2,400) |  | $ | 4.35
Outstanding, end of period | ​ | ​ | 20,400 | ​ | $ | 14.39 | ​ |  | 20,400 | ​ | $ | 14.39 | ​ |  | 12,000 | ​ | $ | 6.55
Exercisable, end of period | ​ | ​ | 13,920 | ​ | $ | 10.99 | ​ |  | 11,280 | ​ | $ | 8.92 | ​ |  | 6,240 | ​ | $ | 6.04
Weighted average fair value at grant date of options granted | ​ | ​ | n/a | ​ | ​ | ​ | ​ | $ | 12.58 | ​ |  |  | ​ | ​ | n/a | ​ |  |
Total intrinsic value of options exercised | ​ | ​ | n/a | ​ | ​ | ​ | ​ | $ | 19,000 | ​ |  |  | ​ | $ | 31,000 | ​ |  |
Total intrinsic value of options outstanding | ​ | $ | 413,000 | ​ | ​ | ​ | ​ | $ | 149,000 | ​ |  |  | ​ | $ | 140,000 | ​ |  |
Total intrinsic value of options exercisable | ​ | $ | 329,000 | ​ | ​ | ​ | ​ | $ | 136,000 | ​ |  |  | ​ | $ | 76,000 | ​ |  |
​ 0, 9,600 and 0 options were granted during the fiscal years ended June 30, 2023, 2022 and 2021, respectively. 0, 1,200 and 2,400 options were exercised during the fiscal years ended June 30, 2023, 2022 and 2021, respectively. 1,200 stock options exercised during the fiscal year ended June 30, 2022 were settled by exchanging 258 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. 2,400 options exercised during the fiscal year ended June 30, 2021 were settled by exchanging 612 shares of the Company common stock which were retired and returned to unissued status upon receipt. $0 was received from the remaining option exercises for each of the fiscal years ended June 30, 2023, 2022 and 2021, and the actual tax benefit realized for the tax deductions from option exercises was $0, $4,000 and $6,000 in fiscal 2023, 2022 and 2021 respectively. The following table summarizes information about stock options outstanding under the 2012 Non-Employee Plan at June 30, 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ | ​ | ​ | ​ | Weighted average | ​ | Weighted | ​ | ​ | ​ | Weighted
​ | ​ | Number | ​ | remaining | ​ | average exercise | ​ | Number | ​ | average exercise
Range of exercise prices | ​ | outstanding |  | contractual life | ​ | price |  | exercisable | ​ | price
$4.35 - $22.93 | ​ | 20,400 | ​ | 6.65 | ​ | $ | 14.39 | ​ | 13,920 | ​ | $ | 10.99
​ | ​ | 20,400 | ​ | 6.65 | ​ | $ | 14.39 | ​ | 13,920 | ​ | $ | 10.99
​ As of June 30, 2023 and 2022, there was $46,000 and $70,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Non-Employee Plan, respectively. 2,640, 6,240 and 5,520 options vested during the years June 30, 2023, 2022 and 2021, respectively. The total grant date fair value of the options vesting during each of the fiscal years ended June 30, 2022, 2021 and 2020 under this plan was $24,000, $39,000 and $18,000, respectively. 2018 Non-Employee Stock Option Plan In December 2018, the stockholders approved the 2018 Non-Employee Stock Option Plan (the “2018 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 100,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2018 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At June 30, 2023, 75,000 stock options were outstanding, 50,720 stock options were exercisable and 0 stock options were available for grant under this plan. No stock options were granted under this plan during the year ended June 30, 2023. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2023 |  | 2022 | ​ | 2021 |
Risk-free interest rates | ​ | n/a | ​ | 1.68 | % | n/a | ​
Expected lives | ​ | n/a | ​ | 6.18 Years | ​ | n/a | ​
Expected volatility | ​ | n/a | ​ | 43 | % | n/a | ​
Expected dividend yields | ​ | n/a | ​ | 0 | % | n/a | ​
​ The following table reflects activity under the 2018 Non-Employee plan for the fiscal year ended June 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2023 | ​ | 2022 | ​ | 2021
​ |  | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average
​ | ​ | Options |  | exercise price | ​ | Options |  | exercise price | ​ | Options |  | exercise price
Outstanding, beginning of year | ​ | ​ | 89,000 | ​ | $ | 14.91 | ​ | ​ | 70,100 | ​ | $ | 11.93 | ​ | ​ | 96,800 | ​ | $ | 11.74
Granted | ​ | ​ | — |  | ​ | — | ​ |  | 23,500 |  | $ | 22.93 | ​ |  | — |  | ​ | —
Forfeited/Lapsed | ​ | ​ | — |  | ​ | — | ​ |  | — |  | ​ | — | ​ |  | (23,500) |  | ​ | 11.68
Exercised | ​ | ​ | (14,000) |  | $ | 15.32 | ​ |  | (4,600) |  | $ | 10.43 | ​ |  | (3,200) |  | ​ | 8.10
Outstanding, end of period | ​ | ​ | 75,000 | ​ | $ | 14.83 | ​ |  | 89,000 | ​ | $ | 14.91 | ​ |  | 70,100 | ​ | $ | 11.93
Exercisable, end of period | ​ | ​ | 50,720 | ​ | $ | 12.87 | ​ |  | 45,040 | ​ | $ | 12.98 | ​ |  | 29,960 | ​ | $ | 11.68
Weighted average fair value at grant date of options granted | ​ | ​ | n/a | ​ | ​ | ​ | ​ | $ | 12.58 | ​ | ​ | ​ | ​ | ​ | n/a | ​ | ​ | ​
Total intrinsic value of options exercised | ​ | $ | 209,000 | ​ | ​ | ​ | ​ | $ | 58,000 | ​ | ​ | ​ | ​ | $ | 29,000 | ​ | ​ | ​
Total intrinsic value of options outstanding | ​ | $ | 1,486,000 | ​ | ​ | ​ | ​ | $ | 561,000 | ​ | ​ | ​ | ​ | $ | 439,000 | ​ | ​ | ​
Total intrinsic value of options exercisable | ​ | $ | 1,104,000 | ​ | ​ | ​ | ​ | $ | 354,000 | ​ | ​ | ​ | ​ | $ | 195,000 | ​ | ​ | ​
​ 0, 23,500 and 0 options were granted during the fiscal years ended June 30, 2023, 2022 and 2021, respectively. 14,000, 4,600 and 3,200 options were exercised during the fiscal years ended June 30, 2023, 2022 and 2021, respectively. 14,000 stock options exercised during the fiscal year ended June 30, 2023 were settled by exchanging 7,235 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. 4,600 stock options exercised during the fiscal year ended June 30, 2022 were settled by exchanging 2,075 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. 3,200 stock options exercised during the fiscal year ended June 30, 2021 were settled by exchanging 1,518 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. $0 was received from the remaining option exercises for each of the fiscal years ended June 30, 2023, 2022 and 2021, and the actual tax benefit realized for the tax deductions from option exercises was $44,000, $12,000 and $6,000 in fiscal 2023, 2022 and 2021, respectively. The following table summarizes information about stock options outstanding under the 2018 Non- Employee Plan at June 30, 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ |  | ​ |  | Weighted average |  | Weighted |  | ​ |  | Weighted
​ | ​ | Number | ​ | remaining | ​ | average exercise | ​ | Number | ​ | average exercise
Range of exercise prices | ​ | outstanding | ​ | contractual life | ​ | price | ​ | exercisable | ​ | price
$8.10 - $22.93 | ​ | 75,000 |  | 6.76 | ​ | $ | 14.83 |  | 50,720 | ​ | $ | 12.87
​ | ​ | 75,000 |  | 6.76 | ​ | $ | 14.83 |  | 50,720 | ​ | $ | 12.87
​ As of June 30, 2023 and 2022, there was $135,000 and $265,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2018 Non-Employee Plan, respectively. 19,680 options vested during each of the years June 30, 2023, 2022 and 2021, respectively. The total grant date fair value of the options vesting during the fiscal year ended June 30, 2023, 2022 and 2021 under this plan was $149,000, $160,000 and $133,000, respectively. 2020 Non-Employee Stock Option Plan In May 2020, the stockholders approved the 2020 Non-Employee Stock Option Plan (the “2020 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 100,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2020 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At June 30, 2023, 56,900 stock options were outstanding, 18,760 stock options were exercisable and 43,100 stock options were available for grant under this plan. 30,000 options were granted under this plan during the year ended June 30, 2023. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2023 |  | 2022 |  | 2021 |
Risk-free interest rates |  | 3.03 - 3.40 | % | 1.68 | % | 0.62 | %
Expected lives |  | 7.23 - 7.27 Years | ​ | 6.18 Years | ​ | 10 Years | ​
Expected volatility |  | 43 | % | 43 | % | 45 | %
Expected dividend yields |  | 0 | % | 0 | % | 0 | %
​ The following table reflects activity under the 2020 Non-Employee plan for the fiscal year ended June 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2023 | ​ | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | Weighted average
​ |  | Options |  | exercise price |  | Options |  | exercise price |  | Options |  | exercise price
Outstanding, beginning of year |  | ​ | 26,900 |  | $ | 18.64 | ​ | ​ | 10,000 |  | $ | 11.40 | ​ | ​ | — |  | ​ | —
Granted |  | ​ | 30,000 | ​ | $ | 27.57 | ​ | ​ | 16,900 | ​ | $ | 22.93 | ​ | ​ | 10,000 | ​ | $ | 11.40
Forfeited/Lapsed | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Exercised |  | ​ | — | ​ |  | — | ​ | ​ | — | ​ |  | — | ​ | ​ | — | ​ |  | —
Outstanding, end of period |  | ​ | 56,900 | ​ | $ | 23.35 | ​ | ​ | 26,900 | ​ | $ | 18.64 | ​ | ​ | 10,000 | ​ | $ | 11.40
Exercisable, end of period |  | ​ | 18,760 | ​ | $ | 20.73 | ​ | ​ | 7,380 | ​ | $ | 16.68 | ​ | ​ | 2,000 | ​ | $ | 11.40
Weighted average fair value at grant date of options granted | ​ | $ | 13.74 | ​ |  |  | ​ | $ | 12.58 | ​ |  | ​ | ​ | $ | 6.10 | ​ |  | ​
Total intrinsic value of options exercised | ​ |  | n/a | ​ |  |  | ​ |  | n/a | ​ |  | ​ | ​ |  | n/a | ​ |  | ​
Total intrinsic value of options outstanding | ​ | $ | 643,000 | ​ |  |  | ​ | $ | 92,000 | ​ |  | ​ | ​ | $ | 68,000 | ​ |  | ​
Total intrinsic value of options exercisable | ​ | $ | 261,000 | ​ |  |  | ​ | $ | 37,000 | ​ |  | ​ | ​ | $ | 14,000 | ​ |  | ​
​ 30,000, 16,900 and 10,000 options were granted during the fiscal years ended June 30, 2023, 2022 and 2021, respectively. No options were exercised during the fiscal years ended June 30, 2023, 2022 and 2021. The following table summarizes information about stock options outstanding under the 2020 Non- Employee Plan at June 30, 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Number | ​ | remaining | ​ | Weighted average | ​ | Number | ​ | Weighted average
Range of exercise prices |  | outstanding |  | contractual life |  | exercise price |  | exercisable |  | exercise price
$11.40 - $30.71 |  | 56,900 |  | 8.59 | ​ | $ | 23.35 |  | 18,760 | ​ | $ | 20.73
​ |  | 56,900 |  | 8.59 | ​ | $ | 23.35 |  | 18,760 | ​ | $ | 20.73
​ As of June 30, 2023 and 2022, there was $344,000 and $135,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2020 Non-Employee Plan, respectively. 11,380, 5,380 and 2,000 options vested during the years June 30, 2023, 2022 and 2021, respectively. The total grant date fair value of the options vesting during the fiscal year ended June 30, 2023, 2022 and 2021 under this plan was $129,000, $55,000 and $12,000, respectively. 2022 Employee Stock Option Plan In December 2022, the stockholders approved the 2022 Employee Stock Option Plan (the “2022 Employee Plan”). The plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 950,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options, which are intended to qualify as incentive stock options (“ISOs”) or non-incentive stock options, to valued employees. Any plan participant who is granted ISOs and possesses more than 10% of the voting rights of the Company’s outstanding common stock must be granted an option with a price of at least 110% of the fair market value on the date of grant. Under the 2022 Employee Plan, stock options may be granted to valued employees with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable, in whole or in part, at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At June 30, 2023, 5,000 stock options were outstanding, 1,000 stock options were exercisable and 945,000 stock options were available for grant under this plan. 5,000 options were granted under this plan during the year ended June 30, 2023. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​
​ |  | 2023 |
Risk-free interest rates |  | 3.84 | %
Expected lives |  | 7.28 Years | ​
Expected volatility |  | 45 | %
Expected dividend yields |  | 0.62 | %
​ The following table reflects activity under the 2022 Employee plan for the fiscal year ended June 30,: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2023
​ | ​ | ​ | ​ | ​ | Weighted average
​ |  | Options |  | exercise price
Outstanding, beginning of year |  | ​ | — |  | ​ | —
Granted |  | ​ | 5,000 | ​ | $ | 40.01
Forfeited/Lapsed | ​ | ​ | — | ​ | ​ | —
Exercised |  | ​ | — | ​ |  | —
Outstanding, end of period |  | ​ | 5,000 | ​ | $ | 40.01
Exercisable, end of period |  | ​ | 1,000 | ​ | $ | 40.01
Weighted average fair value at grant date of options granted | ​ | $ | 19.77 | ​ |  |
Total intrinsic value of options exercised | ​ |  | n/a | ​ |  |
Total intrinsic value of options outstanding | ​ | $ | — | ​ |  |
Total intrinsic value of options exercisable | ​ | $ | — | ​ |  |
​ 5,000 options were granted during the fiscal year ended June 30, 2023. No options were exercised during the fiscal year ended June 30, 2023. The following table summarizes information about stock options outstanding under the 2022 Employee Plan at June 30, 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Number | ​ | remaining | ​ | Weighted average | ​ | Number | ​ | Weighted average
Range of exercise prices |  | outstanding |  | contractual life |  | exercise price |  | exercisable |  | exercise price
$40.01 |  | 5,000 |  | 9.95 | ​ | $ | 40.01 |  | 1,000 | ​ | $ | 40.01
​ |  | 5,000 |  | 9.95 | ​ | $ | 40.01 |  | 1,000 | ​ | $ | 40.01
​ As of June 30, 2023, there was $74,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2020 Non-Employee Plan. 1,000 options vested during the year ended June 30, 2023. The total grant date fair value of the options vesting during the fiscal year ended June 30, 2023 under this plan was $20,000.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration